PhD project aims to develop a defined, scalable microbiota-based therapy—“consortium-in-a-pill”—to replace FMT for treating cancer cachexia. This condition, marked by muscle wasting and inflammation, affects most cancer patients and lacks effective therapies. The project involves selecting beneficial microbial strains as well as metabolites identified by other MiCCrobioTAckle researchers, formulating synergistic consortia, and optimizing anaerobic cultivation. The project will bridge preclinical findings with industrial product development, laying the groundwork for a GMP-compliant oral therapy that supports muscle function and reduces systemic inflammation in cachectic patients.
